|
| Press Releases |
|
 |
|
| Tuesday, August 27, 2024 |
|
|
First Results From Lexaria's Second GLP-1 Human Pilot Study |
| more info >> |
|
| Thursday, August 22, 2024 |
|
|
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Wednesday, August 21, 2024 |
|
|
Positive Interim Blood Sugar Results From Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Monday, August 19, 2024 |
|
|
Positive Results from Lexaria's Molecular Characterization Study Monomeric form of GLP-1 drug preserved by DehydraTECH |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings from its applied research program together with the National Research Council of Canada ("NRC") that evaluated important mode of action facets of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide. more info >> |
|
| Monday, July 8, 2024 |
|
|
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards. more info >> |
|
| Wednesday, May 8, 2024 |
|
|
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study participants has already concluded. more info >> |
|
| Monday, May 6, 2024 |
|
|
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide, related to its mode of action and performance. more info >> |
|
| Tuesday, April 16, 2024 |
|
|
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party ethics review board, for human pilot study #2 (the "Study"), investigating GLP-1 drugs and DehydraTECH. more info >> |
|
| Tuesday, April 2, 2024 |
|
|
Lexaria Awarded New Patents |
| more info >> |
|
| Thursday, March 14, 2024 |
|
|
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
美國馬球協會擴大大學合作計畫 2026賽季隊伍數創紀錄達70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
美国马球协会扩大大学合作计划，2026赛季参赛队伍创纪录达70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 5, 2026 20:00 HKT/SGT
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 17:00: JST
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 16:00 HKT/SGT
|
|
|
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 5, 2026 16:47 JST
|
|
|
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 5, 2026 16:38 JST
|
|
|
Galaxy Corporation Leads "K-Entertech" IPO Rush as Nasdaq Vice Chairman's Surprise Visit Boosts Listing Prospects
Mar 5, 2026 15:30 HKT/SGT
|
|
|
康哲药业自研INHBE小核酸药物获批超重/肥胖临床
Mar 5, 2026 15:13 HKT/SGT
|
|
|
康哲藥業自研INHBE小核酸藥物獲批超重/肥胖臨床
Mar 5, 2026 15:02 HKT/SGT
|
|
|
Formerra 任命 Tom Kelly 為首席執行官
Mar 5, 2026 14:11 HKT/SGT
|
|
|
富士通Japan、大分市民図書館において「デジタル認証アプリ」を活用したWeb利用者登録サービスを構築し、運用を開始
Mar 5, 2026 13:25: JST
|
|
|
Honda、米国生産乗用車の日本導入を決定
Mar 5, 2026 12:50: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
